NANOBIOTIX Virtual Event on NBTXR3 and Immunotherapy in Cancer, June 18, 2024

June 12, 2024 -- NANOBIOTIX, a biotechnology company in the late stages of clinical development, is pioneering innovative physics-driven approaches to broaden cancer treatment options. The company has announced a virtual Key Opinion Leader (KOL) event scheduled for Tuesday, June 18, 2024, from 9:00-10:30 AM EDT / 3:00-4:30 PM CEST.

The event will feature distinguished KOLs, including Dr. Colette Shen, MD, PhD, and Dr. Ari Rosenberg, MD, who are the Coordinating Investigators for Study 1100, along with moderator Dr. Jeffrey Bockman, PhD. These experts will join Dr. Sebastien Paris, PhD, from Nanobiotix, to present a comprehensive review of NBTXR3. This presentation follows the recent data shared at the 2024 Annual Meeting of the American Society for Clinical Oncology (ASCO), which highlighted disease control and tumor response in patients treated with radiotherapy-activated NBTXR3, followed by anti-PD-1 therapy for second-line or further treatments in those with recurrent or metastatic head and neck squamous cell carcinoma who are either naïve or resistant to prior anti-PD-1 therapy.

The virtual session, titled "Nanobiotix KOL Call to Discuss the Role of NBTXR3 and Immune Oncology in Advancing Head & Neck Cancer," aims to delve into several critical areas:
- The mechanisms of action of NBTXR3
- The local and systemic responses elicited by NBTXR3
- The clinical presentation and treatment landscape for head and neck cancer patients, highlighting the unmet medical needs
- Insights from the 1100 study on NBTXR3 in recurrent/metastatic head and neck cancer

Interested participants can register online to watch the presentation live, with a replay available shortly afterward through the same webcast link. This session will also be archived on the company's website. It is recommended that participants join the event 10 minutes before it starts. Additionally, participants are encouraged to email their questions in advance to investors@nanobiotix.com.

About NANOBIOTIX

Founded in 2003, Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France. The company has been publicly listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. Nanobiotix has subsidiaries in Cambridge, Massachusetts, among other locations.

Nanobiotix owns more than 25 patent families related to three core nanotechnology platforms, which have applications in oncology, bioavailability and biodistribution, and disorders of the central nervous system. The company's overarching mission lies in pushing the boundaries of scientific understanding to expand the possibilities for human health, driven by a commitment to impactful innovation.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!